Astellas Pharma (OTCMKTS:ALPMY) Sets New 12-Month Low – Here’s What Happened

Astellas Pharma Inc. (OTCMKTS:ALPMY)’s stock price reached a new 52-week low during trading on Friday . The company traded as low as $9.05 and last traded at $9.60, with a volume of 228458 shares trading hands. The stock had previously closed at $9.44.

Astellas Pharma Trading Up 1.7 %

The company’s 50 day simple moving average is $9.91 and its two-hundred day simple moving average is $10.98. The company has a quick ratio of 0.86, a current ratio of 1.10 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $17.37 billion, a price-to-earnings ratio of 45.72 and a beta of 0.34.

Astellas Pharma (OTCMKTS:ALPMY) last announced its earnings results on Wednesday, October 30th. The company reported $0.13 earnings per share for the quarter. Astellas Pharma had a return on equity of 10.40% and a net margin of 3.26%. The firm had revenue of $3.11 billion for the quarter. As a group, research analysts anticipate that Astellas Pharma Inc. will post 0.61 earnings per share for the current fiscal year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.